Warning Letter — BMC Medical Co., Ltd.
The FDA issued a Warning Letter to BMC Medical Co., Ltd. following a review by the Center for Devices and Radiological Health. The specific nature of the violations is not detailed in the provided excerpt, but it stems from compliance deficiencies identified during regulatory oversight.
This affects BMC Medical Co., Ltd., its global regulatory and quality departments, and potentially any distributors or stakeholders involved in the supply chain for their medical devices.
A Warning Letter from CDRH indicates that prior responses to inspection observations were likely deemed inadequate by the agency. This elevates the enforcement status of the firm, which may lead to the withholding of premarket approvals or the restriction of certificates to foreign governments until the violations are corrected. Regulatory teams should interpret this as a signal to prioritize robust corrective and preventive action (CAPA) plans.
Conduct a thorough audit of the Quality Management System (QMS) to ensure alignment with CDRH expectations, specifically focusing on documentation and process control. Ensure all responses to initial FDA inspection findings are comprehensive and supported by verifiable evidence of remediation.
FDA Warning Letter issued to: BMC Medical Co., Ltd.. 05/20/2026 — Center for Devices and Radiological Health. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bmc-medical-co-ltd-725759-05202026
Open in openFDA / FDA.gov